255 related articles for article (PubMed ID: 26453012)
21. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor-positive and triple-negative breast cancer cells.
Kulkarni YM; Yakisich JS; Azad N; Venkatadri R; Kaushik V; O'Doherty G; Iyer AKV
Tumour Biol; 2017 Jun; 39(6):1010428317705331. PubMed ID: 28618929
[TBL] [Abstract][Full Text] [Related]
23. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.
Wang T; Subramanian C; Yu M; White PT; Kuai R; Sanchez J; Moon JJ; Timmermann BN; Schwendeman A; Cohen MS
Surgery; 2019 Dec; 166(6):1168-1175. PubMed ID: 31371177
[TBL] [Abstract][Full Text] [Related]
24. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
25. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
27. Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
Bräutigam K; Mitzlaff K; Uebel L; Köster F; Polack S; Pervan M; Steinert G; Rody A; Liedtke C
Anticancer Res; 2016 Jun; 36(6):2759-66. PubMed ID: 27272786
[TBL] [Abstract][Full Text] [Related]
28. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
[TBL] [Abstract][Full Text] [Related]
29. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity.
Roberts LS; Yan P; Bateman LA; Nomura DK
ACS Chem Biol; 2017 Apr; 12(4):1133-1140. PubMed ID: 28248089
[TBL] [Abstract][Full Text] [Related]
30. Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
Hu Z; Shen R; Campbell A; McMichael E; Yu L; Ramaswamy B; London CA; Xu T; Carson WE
Cancer Immunol Res; 2018 Jun; 6(6):671-684. PubMed ID: 29622581
[TBL] [Abstract][Full Text] [Related]
31. In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer.
Kutty RV; Chia SL; Setyawati MI; Muthu MS; Feng SS; Leong DT
Biomaterials; 2015 Sep; 63():58-69. PubMed ID: 26081868
[TBL] [Abstract][Full Text] [Related]
32. Nanosoldiers: A promising strategy to combat triple negative breast cancer.
Pawar A; Prabhu P
Biomed Pharmacother; 2019 Feb; 110():319-341. PubMed ID: 30529766
[TBL] [Abstract][Full Text] [Related]
33. Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells.
Shemesh CS; Hardy CW; Yu DS; Fernandez B; Zhang H
Photodiagnosis Photodyn Ther; 2014 Jun; 11(2):193-203. PubMed ID: 24657627
[TBL] [Abstract][Full Text] [Related]
34. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
35. NOTCH4 is a potential therapeutic target for triple-negative breast cancer.
Nagamatsu I; Onishi H; Matsushita S; Kubo M; Kai M; Imaizumi A; Nakano K; Hattori M; Oda Y; Tanaka M; Katano M
Anticancer Res; 2014 Jan; 34(1):69-80. PubMed ID: 24403446
[TBL] [Abstract][Full Text] [Related]
36. Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells.
Abdelhamed S; Yokoyama S; Refaat A; Ogura K; Yagita H; Awale S; Saiki I
Anticancer Res; 2014 Apr; 34(4):1893-9. PubMed ID: 24692724
[TBL] [Abstract][Full Text] [Related]
37. Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.
Stewart DA; Winnike JH; McRitchie SL; Clark RF; Pathmasiri WW; Sumner SJ
J Proteome Res; 2016 Sep; 15(9):3225-40. PubMed ID: 27447733
[TBL] [Abstract][Full Text] [Related]
38. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
[TBL] [Abstract][Full Text] [Related]
39. H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells.
Pandolfi L; Bellini M; Vanna R; Morasso C; Zago A; Carcano S; Avvakumova S; Bertolini JA; Rizzuto MA; Colombo M; Prosperi D
Biomacromolecules; 2017 Oct; 18(10):3318-3330. PubMed ID: 28886247
[TBL] [Abstract][Full Text] [Related]
40. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
